Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial

Plain-language guide to PMID 20124230 (2010): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 20124230
Journal: Annals of internal medicine
Year: 2010
Study type: Randomized Controlled Trial
Authors: Schnoll RA et al. (7 authors)
DOI: 10.7326/0003-4819-152-3-201002020-00005
Registered trial: NCT05487807, NCT00364156

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Tobacco dependence is a chronic, relapsing condition that may require extended treatment.

The generalizability of the findings may be limited because participants were smokers without medical comorbid conditions who were seeking treatment, and differences in adherence across treatment groups were detected.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Participants and all research personnel except the database manager were blinded to randomization.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Parallel randomized, placebo-controlled trial from September 2004 to February 2008.

The primary outcome was biochemically confirmed point-prevalence abstinence at weeks 24 and 52.

Secondary outcomes were continuous and prolonged abstinence, lapse and recovery events, cost per additional quitter, and side effects and adherence.

What Was Measured

Topics PubMed links to this paper include Administration, Cutaneous, Nicotine and Smoking.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Annals of internal medicine), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.